Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>HTSC Lifts JD HEALTH's TP to HKD77.4 w/ Higher Earnings Forecasts
Recommend 4 Positive 10 Negative 3 |
||||
|
||||
|
Huatai Securities has published a report predicting JD HEALTH (06618.HK)'s 4Q25 revenue to have grown by 22.7% YoY on the strength of the heightened online penetration rate in the pharmaceutical category and supply chain advantages. The broker also expects JD HEALTH to have recorded non-IFRS operating profit of RMB260 million. In addition, the seasonal misalignment of the flu might provide short-term support for revenue growth in the last quarter. Throughout 2025, JD HEALTH is anticipated to have seen its revenue soar by 25% YoY to RMB72.7 billion and non-IFRS operating profit reach RMB4.11 billion. Huatai Securities has raised its 2025-27 non-IFRS net profit forecasts for the company by 11.6%/ 15.6%/ 22.4%. Huatai Securities has lifted its target price for JD HEALTH from HKD68.3 to HKD77.4 and kept the Buy rating unchanged. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
